Medical therapy for benign prostatic hyperplasia - Present and future impact

American Journal of Managed Care

Volumn 13, Issue 1 SUPPL., 2007, Pages

  Issa, Muta M ^a   Regan, Timothy S ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CLINICAL DECISION MAKING; CLINICAL FEATURE; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MALE; MANAGED CARE; MONOTHERAPY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; URINE RETENTION; VASODILATATION;

AGED; ENZYME INHIBITORS; FORECASTING; HEALTH CARE COSTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; URINARY RETENTION;

EID: 33847199023     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. US Census Bureau. US interim projections by age, sex, race, and Hispanic origin. Available at: www. census.gov/ipc/www/usinterimproj/ natprojtab02a.pdf. Accessed October 25, 2006.
2. Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006; 12:S83-S89.
3. Naslund MJ, Chiao E, Black L, Eaddy MT. The hidden condition: status, challenges, and opportunities in the management of enlarged prostate for managed care. Am J Manag Care. 2006;12(4 suppl):S76-S82.
4. Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. BMJ. 2006;333:535-539.
5. Roehrbom CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(suppl 9):S3-S14.
6. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267-273.
7. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256-1261.
8. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97(suppl 2):3-6.
9. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422-1426.
10. Naslund MJ, Issa MM, Grogg AL, et al. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care. 2006;12(4 suppl):S111-S116.
11. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline Number 8, AHCPR Publication No. 94-0582. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; February 1994. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid= hstat6.chapter.17571. Accessed January 2, 2007.
12. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
13. Roehrbom CG, McConnell JD, Barry MJ, et al. Guideline on the management of benign prostatic hyperplasia (BPH). 2003; updated 2006. American Urological Association. Available at: http://www.aua2004.org/ guidelines/bph.cfm. Accessed January 8, 2007.
14. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173:1309-1313.
15. Goluboff ET, Olsson CA. Urologist on a tightrope: coping with a changing economy. J Urol. 1994;151:1-4.
16. Baine WB, Yu W, Summe JP, Weis KA. Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from 1991 to 1995. J Urol. 1998;160:816-820.
17. Wasson JH, Bubolz TA, Lu-Yao GL, et al. Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol. 2000;164:1212-1215.
18. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health status in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717.
19. Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S90-S98.
20. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(suppl 9):S3-S10.
21. Lowe FC. Goals for benign prostatic hyperplasia therapy. Urology. 2002;59(2 suppl 1):1-2.
22. Speakman MJ, Kirby RS, Joyce A, et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93:985-990.
23. Gee WF, Holtgrewe HL, Blute ML, et al. 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol. 1998;160:1804-1807.
24. McConnell JD, Roehrbom CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
25. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64:1081-1088.
26. Proscar® (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; January 2006. Available at: http://www.merck.com/ product/ usa/pi_circulars/p/proscar_pi.pdf. Accessed January 8, 2007.
27. Avodart® (dutasteride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2005. Available at: http://us.gsk.com/products/ assets/ us_avodart.pdf. Accessed January 8, 2007.
28. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338:557-563.
29. Roehrbom CG, Bruskewitz R, Nickel JC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171: 1194-1198.
30. Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5 alpha reductase. Rev Urol. 2005;7:203-210.
31. Baldwin KC, Ginsberg PC, Roehrbom CG, Harkawav RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology. 2001;58:203-209.
32. Barkin J, Guimarães M, Jacobi G, et al. Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha reductase inhibitor dutasteride. Eur Urol. 2003; 44:461-466.
33. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(suppl 9): S31-S39.
34. Hagerty JA, Ginsberg PC, Harkaway RC. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in clinical practice. Presented at: the 2004 Annual Meeting of the American Urological Association; May 8-13, 2004; San Francisco, Calif. Poster 1353.
35. Macdiarmid S, Chen A, Tu N, Aquilina J, Peters K. Effects of tamsulosin and extended-release oxybutynin on lower urinary tract symptoms in men. Abstract presented at: the 2006 Annual Meeting of the American Urological Association; May 20-25, 2006; Atlanta, Ga. Abstract 1638.
36. Roehrbom CG, McVary K, Kaminetsky J, et al. The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Abstract presented at: the 2006 Annual Meeting of the American Urological Association; May 20-25, 2006; Atlanta, Ga. Abstract 1636.